A5033985179- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Diet and metabolism studies
- Esophageal Cancer Research and Treatment
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Clinical Nutrition and Gastroenterology
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Helicobacter pylori-related gastroenterology studies
- PI3K/AKT/mTOR signaling in cancer
Unified Szent István and Szent László Hospital
2015-2025
Országos Pszichiátriai és Neurológiai Intézet
2022
Roche (Switzerland)
2021
University of Szeged
2021
National Health Research Institutes
2019
Centrum Onkologii
2019
Hungarian Academy of Sciences
2014
Semmelweis University
1989-2014
University of Verona
2014
KU Leuven
2009-2013
We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer sought associations between mutation status KRAS gene in tumors clinical response to cetuximab.We randomly assigned patients with epidermal growth factor receptor-positive unresectable metastases receive FOLFIRI either alone or combination cetuximab. The primary end point was progression-free survival.A total 599 received FOLFIRI, alone....
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating RAS may also be negative predictive biomarkers for anti-EGFR
Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as monotherapy for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The Panitumumab Randomized Trial in Combination With Chemotherapy Metastatic Colorectal Cancer to Determine Efficacy (PRIME) was designed evaluate the efficacy and safety of panitumumab plus infusional fluorouracil, leucovorin, oxaliplatin (FOLFOX4)...
Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic in treatment advanced colorectal cancer. We took advantage PETACC-3, an adjuvant trial with 3,278 patients stage II to III colon cancer, evaluate and BRAF tumor mutation status this setting.Formalin-fixed paraffin-embedded tissue blocks (n = 1,564) were prospectively collected DNA was extracted from sections 1,404 cases. Planned analysis exon 2 15 mutations performed by allele-specific real-time...
This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer.Patients were randomly assigned to receive GemCap (oral 650 mg/m2 twice daily on days 1 14 1,000 by 30-minute infusion 8 every 3 weeks) or (1,000 weekly for 7 weeks, followed a 1-week break, then weeks 4 weeks). Patients stratified according center, Karnofsky performance score (KPS), presence pain, disease extent.A total 319...
BackgroundThe Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) demonstrated that panitumumab–FOLFOX4 significantly improved progression-free survival (PFS) versus FOLFOX4 as first-line treatment of wild-type (WT) KRAS metastatic (mCRC), the primary end point study.Patients and methodsPatients were randomized 1:1 panitumumab 6.0 mg/kg every 2 weeks + (arm 1) or 2). This prespecified final descriptive analysis efficacy...
Purpose Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage. Methods This study was conducted in 24 countries 146 centers. One thousand fifty-three patients were stratified (center, number of metastatic sites, prior adjuvant therapy, measurable cancer) randomly assigned. received either S-1 at 50 mg/m 2 divided two daily doses for 21 days...
PURPOSE The primary objective of this randomized, multicenter, phase III trial was to investigate whether the addition irinotecan de Gramont infusional fluorouracil (FU)/leucovorin (LV) adjuvant regimen (LV5FU2) would improve disease-free survival (DFS) in patients with stage colon cancer. PATIENTS AND METHODS After curatively intentioned surgery, II and cancer were randomly allocated surgery receive LV5FU2 (LV 200 mg/m(2) as a 2-hour infusion, followed by FU; 400 bolus then 600 continuous...
This randomized, open-label trial compared the efficacy and safety of adjuvant
LBA3 Background: PTK787/ZK 222584 (PTK/ZK) is a novel, oral, small molecule, anti-angiogenesis compound that blocks tyrosine kinase signaling from all known vascular endothelial growth factor (VEGF) receptors. Phase I/II studies of PTK/ZK as single agent showed it safe and well tolerated. Dose response was observed by DCE-MRI. An expanded phase study evaluating escalating doses in combination with oxaliplatin/5-FU/LV first-line therapy metastatic colorectal cancer (CRC) demonstrated...
To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that bevacizumab (anti-VEGF-A monoclonal antibody) in combination chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC).HORIZON III [Cediranib Plus FOLFOX6 Versus Bevacizumab Patients With Untreated Metastatic Colorectal Cancer] had an adaptive phase II/III design. randomly assigned 1:1:1 received mFOLFOX6 [oxaliplatin 85 mg/m(2) and...